Slide 1: Annual General Meeting: Chairman's Address and Presentation by Dr Grant Rawlin
ASX Release 23 November 2009 For personal use only Immuron Limited ABN 80 063 114 045 Annual General Meeting Chairman’s Address and Presentation by Dr Grant Rawlin Corporate Details: and ASX Code: IMC Distribution Agreement with OTCQX Code: IMROY (U.S.) Nycomed Australia Directors: Chairman: Prof. C
Slide 2: Chairman's Address to Annual General Meeting
. For personal use only Chairman’s Address to Annual General Meeting 23 November 2009 Good morning ladies and gentlemen. It is my pleasure to welcome you to the 2009 Annual General Meeting of Immuron Limited. I’m sure you know that it has been a busy year for the Company: • There have been significa
Slide 3: Hadassah Medical Center
of the funds raised will used to meet the projected research and development expenditure associated with the very important links with the Hadassah Medical Center in Jerusalem. Some of the funds raised will be used to fund new research and development projects. Hadassah Medical Center For personal u
Slide 4: Market reach of Travelan and research projects
So for shareholders who have been strong supporters of this product in the past, the plan is that whilst the name ‘Travelan’ will not change, it will be sold under the name of the world’s 15th largest provider of over the counter products. In preparation for the commercialisation of products into th
Slide 5: Chairman's conclusion
interaction with key scientists and board members as the current and new directions are developed. In conclusion, the coming year should be an exciting period in terms of our research and For personal use only commercialisation potential as the current clinical trials are completed, and we undertake
Slide 6: Forward Looking Statements
<title> For personal use only ASX:IMC; OTCQX: IMROY Annual General Meeting www.immuron.com 23rd November, 2009 Forward Looking Statements This presentation contains forward-looking statements which are subject to risks and uncertainties. These statements include those regarding the therapeutic and c
Slide 7: 2010 – A pivotal year: what to expect
<title> Dr Grant Rawlin, CEO Immuron For personal use only A new hands-on CEO based in Australia: to bring on the new direction of Immuron. Developed the harvesting system and regulatory stance that is core to our company – i.e. the core platform from lab to market. Developed the patent portfolio. W
Slide 8: The Nycomed license
<title> The Nycomed license For personal use only z Nycomed: term sheet is now agreed to license Travelan and Travelan product extensions for sale in Australia/New Zealand. z To be sold as under ‘Travelan’ trademark under Nycomed label and supported by the Nycomed sales force. z First Nycomed packag
Slide 9: 2010 – A pivotal year: clinical trials and Influenza A
<title> 2010 – A pivotal year: what to expect For personal use only • Complete the current Phase 2 clinical trials • HIV adjunct therapy (Australia), • HIV adjunct therapy – Cleveland Clinic (USA) • Inflammatory Bowel Disease (Tel Aviv) • Mucositis prevention (Tel Aviv) Look for news of results, ana
Slide 10: So what's new? The next months
<title> So what’s new? The next 18 months. Building the new technologies For personal use only Building on the new alliance Immuron/Hadassah: “Ilan and Rawlin” Building on what? o Immunotherapy technology (Yaron) { R and D in 2 countries plus a responsive clinical trials unit – what an advantage! {